Akero Therapeutics AKRO
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Akero Therapeutics (AKRO) Business Model and Operations Summary
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Key Insights
Akero Therapeutics (AKRO) Core Market Data and Business Metrics
Latest Closing Price
$41.95Market Cap
$3.34 BillionPrice-Earnings Ratio
-11.19Total Outstanding Shares
79.62 Million SharesTotal Employees
63Dividend
No dividendIPO Date
June 20, 2019SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
601 Gateway Boulevard, Suite 350, South San Francisco, CA, 94080
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 976,420 Shares | 5.33 | 3/14/2025 | 5,203,442 Shares |
| 789,178 Shares | 6.4 | 2/28/2025 | 5,052,816 Shares |
| 1,092,126 Shares | 4.38 | 2/14/2025 | 4,785,670 Shares |
| 3,056,252 Shares | 1.19 | 1/31/2025 | 3,628,575 Shares |
| 928,361 Shares | 3.61 | 1/15/2025 | 3,350,004 Shares |
| 660,464 Shares | 5.01 | 12/31/2024 | 3,309,161 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $445.85 Million |
| Net Cash Flow From Operating Activities, Continuing | $-230.11 Million |
| Net Cash Flow, Continuing | $106.03 Million |
| Net Cash Flow From Financing Activities | $445.85 Million |
| Net Cash Flow From Operating Activities | $-230.11 Million |
| Net Cash Flow From Investing Activities | $-109.71 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Basic Earnings Per Share | $-3.75 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Common Stock Dividends | $0 |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Diluted Earnings Per Share | $-3.75 |
| Net Income/Loss Attributable To Parent | $-252.06 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $678,000 |
| Comprehensive Income/Loss | $-251.38 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-251.38 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Equity | $750.11 Million |
| Cash | $797.83 Million |
| Other Current Liabilities | $29.56 Million |
| Liabilities And Equity | $825.89 Million |
| Wages | $1.17 Million |
| Assets | $825.89 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||